We are live on ! Find out more

Abivax

ABVX

Market cap $7.62B

87.37 USD

-0.78

0.88%

At close Updated Oct 12, 11:05 AM EDT

1 day

-0.88%

5 days

-6.73%

1 month

-23.08%

3 months

-35.75%

6 months

-27.98%

Year to date

-34.69%

1 year

-8.64%

5 years

952.65%

10 years

952.65%

About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Employees: 69

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 44.4%

Negative 11.1%

Cedar Grove Capital Q3 2026 Portfolio Update

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.

Cedar Grove Capital Q3 2026 Portfolio Update

Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts

Abivax Société Anonyme is advancing obefazimod for ulcerative colitis and Crohn's, with recent safety concerns now largely addressed. ABVX raised $920 million, extending its cash runway into Q4 2029 and strengthening its negotiating position for potential M&A. ABVX stock is fairly valued in the $90s, with upside contingent on a favorable UC label and positive Phase 2b CD data in 2027.

Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts

These Analysts Slash Their Forecasts On Abivax Following H1 Results

Abivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.

These Analysts Slash Their Forecasts On Abivax Following H1 Results

Abivax Presents Business Updates and First Half 2026 Financial Results

Abivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax's Chemistry, Manufacturing and Controls (“CMC”), Quality and Information Technology (“IT”) functions Cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritten public offering, provides cash runway into Q4 2029 Royalty certificates buy-back completed in Q2 2026 materially reduces royalty overhang, further strengthening Abivax's debt-free financial position and flexibility to support future commercialization efforts PARIS, France – September 21, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, reported today business updates and financial results for the six months ended June 30, 2026. The half-year financial statements, approved by the Company's Board of Directors on September 18, 2026, have been reviewed by the Company's statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities on September 21, 2026.

Abivax Presents Business Updates and First Half 2026 Financial Results

Accenture, Abivax and 3 Stocks to Watch Heading Into Monday

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Accenture, Abivax and 3 Stocks to Watch Heading Into Monday

Zacks Investment Research

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

4 Biotech Stocks to Watch as Potential Takeover Targets

Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

ABIVAX Société Anonyme (NASDAQ:ABVX) will release its first-half earnings report after the closing bell on Monday, Sept. 21.

Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Zacks Investment Research

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Abivax: Obefazimod Goes The Distance And So Does My Buy Rating

Abivax (ABVX) maintains a Buy rating, supported by robust Phase 3 maintenance data for obefazimod in ulcerative colitis. ABVX demonstrated clinical remission rates of 50.8%–51.3% at week 44, with strong secondary endpoints and a favorable safety profile. A recent $920M capital raise funds operations into Q4 2029, enabling standalone commercialization and strengthening strategic positioning.

Abivax: Obefazimod Goes The Distance And So Does My Buy Rating

Zacks Investment Research

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

After reaching an important support level, Abivax SA Sponsored ADR (ABVX) could be a good stock pick from a technical perspective. ABVX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

See News Rankings

Price charts implemented using Lightweight Charts™